Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL612330 | 0.73 | ALDH1A1 (0.45) | PKM | |
| SCHEMBL6469372 | 0.73 | PKM (0.35) | PKM | |
| SCHEMBL15704382 | 0.71 | ALDH1A1 (0.34) | PKM | |
| SCHEMBL785793 | 0.71 | ALDH1A1 (0.31) | PKM | |
| SCHEMBL55745 | 0.71 | ALDH1A1 (0.31) | PKM | |
| SCHEMBL25354731 | 0.71 | TRPA1 (0.39) | — | |
| SCHEMBL1002242 | 0.70 | ALDH1A1 (0.48) | PKM | |
| Hydrochloric Acid SCHEMBL17491131 | 0.70 | ALDH1A1 (0.30) | PKM | |
| SCHEMBL2604453 | 0.69 | KDM4E (0.58) | PKM | |
| SCHEMBL566106 | 0.69 | IDO1 (0.39) | PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050192279-A1 | Pyridazinones as antagonists of alpha4 integrins | JANSSEN PHARAMACEUTICA, N.V. (BE) | 2005-09-01 | — | — | US | claimed |
| US-20230033021-A1 | TREATMENT OF A DISEASE OF THE GASTROINTESTINAL TRACT WITH AN INTEGRIN INHIBITOR | GLAS USA LLC | 2023-02-02 | — | — | US | disclosed |
| US-20050192279-A1 | Pyridazinones as antagonists of alpha4 integrins | JANSSEN PHARAMACEUTICA, N.V. (BE) | 2005-09-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230033021-A1 | TREATMENT OF A DISEASE OF THE GASTROINTESTINAL TRACT WITH AN INTEGRIN INHIBITOR | ITGAL, ITGB2, ITGB1 | PKM 2739/4885 |
| US-20050192279-A1 | Pyridazinones as antagonists of alpha4 integrins | ITGB4, ITGA4, ITGB5 | PKM 1769/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.